EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The impact of ctDNA on metastatic cancer management: Current trends and future directions

Omveer Singh, Usha Kumari Sah, Jay Chandra, Saraswati Patel

Oral Oncology Reports · 2025-03 · 13 · 100705

DOI: 10.1016/j.oor.2024.100705 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oral Oncology Reports, 2025-03. Verfasst von Omveer Singh und 3 weiteren Autor:innen. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Circulating tumor DNA (ctDNA) has emerged as a transformative tool in metastatic cancer management, offering a non-invasive approach for diagnosis, monitoring, and personalized treatment. This report examines recent advancements in ctDNA technology and its impact on oncology. ctDNA enables early cancer detection with high sensitivity (up to 85 %) and specificity (95 %) and provides valuable insights into disease progression and treatment efficacy. Technological innovations, such as next-generation sequencing (NGS) and artificial intelligence (AI), have enhanced the accuracy of ctDNA analysis. Furthermore, ctDNA facilitates personalized treatment strategies by identifying specific genetic mutations, improving therapeutic outcomes. The growing acceptance of ctDNA-based tests, alongside ongoing research into cost reduction and expanded applications, underscores its potential to revolutionize cancer care. This report highlights current trends, recent research, and future directions for integrating ctDNA into routine clinical practice. • ctDNA offers up to 85 % sensitivity and 95 % specificity for early cancer detection. • ctDNA levels correlate with tumor burden, aiding in treatment efficacy and disease progression assessment. • Identifies genetic mutations to tailor therapies, improving patient outcomes. • Enhanced by next-generation sequencing and AI for better mutation detection. • Promising applications in predicting immunotherapy response and reducing assay costs for broader accessibility.

Zitieren

APA

Singh, O., Sah, U. K., Chandra, J., & Patel, S. (2025). The impact of ctDNA on metastatic cancer management: Current trends and future directions. Oral Oncology Reports, 13, 100705. https://doi.org/10.1016/j.oor.2024.100705

Vancouver

Singh O, Sah UK, Chandra J, Patel S. The impact of ctDNA on metastatic cancer management: Current trends and future directions. Oral Oncology Reports. 2025;13:100705. doi:10.1016/j.oor.2024.100705

BibTeX
@article{Singh2025,
  author = {Singh, Omveer and Sah, Usha Kumari and Chandra, Jay and Patel, Saraswati},
  title = {The impact of ctDNA on metastatic cancer management: Current trends and future directions},
  journal = {Oral Oncology Reports},
  year = {2025},
  volume = {13},
  pages = {100705},
  doi = {10.1016/j.oor.2024.100705}
}
Kostenlos starten →